Generated August 2026 · Clinical Deep Dive 0 Comments Until June 2026, choosing between the two FDA-approved APOC3 inhibitors was a narrow question: same rare disease, same silenced protein, different injection interval. That calculus changed when the FDA approved olezarsen (Tryngolza) for severe hypertriglyceridemia (sHTG), extending its label beyond familial chylomicronemia syndrome (FCS) to a …
Read More
Deep Dive: APOC3 Inhibitors: Tryngolza vs Redemplo
